Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBT (2016 - 2026)

Gyre Therapeutics has reported EBT over the past 16 years, most recently at -$19.7 million for Q4 2025.

  • Quarterly EBT fell 4427.13% to -$19.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.2 million through Dec 2025, down 123.58% year-over-year, with the annual reading at -$5.2 million for FY2025, 123.58% down from the prior year.
  • EBT was -$19.7 million for Q4 2025 at Gyre Therapeutics, down from $7.6 million in the prior quarter.
  • Over five years, EBT peaked at $51.6 million in Q2 2022 and troughed at -$100.3 million in Q4 2023.
  • The 5-year median for EBT is $901500.0 (2024), against an average of -$6.9 million.
  • Year-over-year, EBT surged 359.42% in 2022 and then tumbled 4427.13% in 2025.
  • A 5-year view of EBT shows it stood at -$20.4 million in 2021, then fell by 11.84% to -$22.8 million in 2022, then crashed by 339.82% to -$100.3 million in 2023, then soared by 99.57% to -$435000.0 in 2024, then tumbled by 4427.13% to -$19.7 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBT are -$19.7 million (Q4 2025), $7.6 million (Q3 2025), and $2.2 million (Q2 2025).